Ticker: RDW

Redwire

Aerospace / Defense Industrials Aerospace & Defense
Price 11.19
Reco Sell Potential 40 Risk 70 Updated 2026-09-10

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Redwire is a company operating in the industrials sector, focusing on space infrastructure and satellite technology. Its core products include satellite systems, space robotics, and advanced manufacturing solutions for space applications. Major business segments encompass satellite services, space logistics, and technology development, with primary revenue sources derived from government contracts and commercial partnerships in the aerospace industry.

Investment Profile

The investment profile of Redwire indicates a focus on growth, given its involvement in emerging technologies within the aerospace sector. However, the company's recent financial performance suggests heightened risk, making it less suitable for conservative investors. The stock may appeal to those with a medium to long-term horizon who are comfortable with volatility and potential fluctuations in value.

Fundamental metrics (experimental) Updated: 2026-09-05
EPS (TTM) — earnings per share for the last 12 months, $
-1.46
Revenue QoQ — quarter-over-quarter revenue growth
20.7%
EPS surprise
-21.6%
20d volatility
2.4%
AI recommendation changes
Date Before After Reason
2026-08-23 Hold Sell Weak fundamentals and high volatility raise concerns.
2026-08-15 Sell Hold Strong revenue growth, but negative EPS and high risk.
2026-08-10 Hold Sell High volatility with weak fundamentals and uncertain outlook.
Analyst forecasts
Date Analyst Action Target Price Then
2026-08-10 Canaccord Genuity Target Raised 14 → 15 13.59
2026-08-09 Jefferies Target Lowered 24 → 15 13.59
2026-08-06 Industrial Alliance Securities Target Raised 15 → 16 11.83
News Page 1 of 1
SpaceX Merck Redwire Eli Lilly

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.